New drug aims to stop virus in transplant patients
NCT ID NCT07368153
First seen Jan 27, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This study tests an IDO-1 inhibitor drug to see if it can safely prevent Epstein-Barr virus (EBV) infection in kidney transplant patients who have never had EBV but receive a kidney from a donor who has. Nine participants will take either the drug or a placebo for 28 days, and researchers will monitor side effects and viral levels. The goal is to find a way to reduce EBV-related health problems after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Basel
Basel, 4031, Switzerland
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IDO-1 inhibitor
What this could lead to
If it works, this could point toward a way to prevent EBV-related complications in kidney transplant patients.
What could go wrong
This is a very small, early-phase trial with only 9 participants, so results may not apply broadly. The drug may cause side effects or fail to prevent EBV infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.